Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Concomitant Use of Oral Anticoagulants With Oral Dipeptidyl Peptidase‐4 Inhibitors and Serious Bleeding Events

Clinical Pharmacology & Therapeutics(2024)10.1002/cpt.3442Source: DataRank Database

Concomitant Use of Oral Anticoagulants With Oral Dipeptidyl Peptidase‐4 Inhibitors and Serious Bleeding Events is a research paper published in Clinical Pharmacology & Therapeutics (2024). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.00)OA: hybridTopics (56)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Charles E. Leonard ORCID,C. M. Brensinger,Warren B. Bilker ORCID,Sophie P. Chung ORCID,John R. Horn ORCID

Live enrichment

PubMed:39262110 PMC:PMC11893511 OpenAlex:https://openalex.org/W4402497214

National Institutes of Health

Grant: R01AG025152

National Institutes of Health

Grant: R01DK102694

National Institutes of Health

Grant: R01AG064589

National Institutes of Health

Grant: R01DA048001

National Institutes of Health

Grant: R01MH130435

National Institutes of Health

Grant: R01AG060975

FWCI

0.00

Citation Percentile

0.3%

hybridLicense: cc-by-nc-nd

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpt.3442

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpt.3442

publisherhttps://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.3442

journalhttps://doi.org/10.1002/cpt.3442

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39262110

Fields of Study

Atrial Fibrillation Management and OutcomesPharmaceutical Practices and Patient OutcomesAntiplatelet Therapy and Cardiovascular DiseasesHumansMaleDipeptidyl-Peptidase IV InhibitorsFemaleAgedAnticoagulantsHemorrhageAdministration, OralAged, 80 and overUnited StatesLisinoprilDatabases, FactualDrug InteractionsCross-Over StudiesAdamantaneDipeptides

MeSH Terms

AdamantaneAdministration, OralAgedAged, 80 and overAnticoagulantsDipeptidesDrug InteractionsDrug Therapy, CombinationFemaleMedicareHemorrhageHumansMaleUnited StatesDatabases, FactualLisinoprilCross-Over StudiesDipeptidyl-Peptidase IV Inhibitors

Keywords

SaxagliptinLisinoprilMedicineApixabanLinagliptinOdds ratioInternal medicineWarfarinConfidence intervalGastroenterologyPharmacologyRivaroxabanEndocrinologyDiabetes mellitusType 2 diabetesInsulinMetforminAngiotensin-converting enzymeBlood pressure

Sustainable Development Goals

SDG 0: Good health and well-being